Ozempic Approved to Safeguard Kidneys in Diabetes Patients: A Game-Changer for Treatment
29 Jan 2025
In a significant development in the treatment of diabetes and its associated complications, the U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) as a medication to reduce the risk of kidney disease in patients with type 2 diabetes. This approval marks an important milestone in diabetes...
Read More